Results 51 to 60 of about 339,213 (296)

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

Cancers, 2020
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer.
Mercedes Nadal-Serrano, B. Morancho, S. Escrivá-de-Romaní, C. B. Bernadó Morales, Antonio Luque, Marta Escorihuela, M. Espinosa Bravo, V. Peg, F. Dijcks, Wim H A Dokter, J. Cortés, C. Saura, J. Arribas   +12 more
semanticscholar   +1 more source

In Vivo Fluorescence Imaging of E-Selectin: Quantitative Detection of Endothelial Activation in Arthritis [PDF]

, 2010
Rheumatoid arthritis (RA) is a chronic progressive systemic inflammatory disease, characterized by synovial inflammation and localized destruction of cartilage and bone.
Gompels, Luke, Gompels, Luke
core   +1 more source

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer

Indian Journal of Medical and Paediatric Oncology, 2019
Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine.
Manikandan Dhanushkodi
doaj   +1 more source

Clinical Pharmacology of Antibody-Drug Conjugates [PDF]

Antibodies, 2021
Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since the approval of first ADC (Gemtuzumab ozogamicin (trade name: Mylotarg)) for the treatment of CD33-positive acute myelogenous leukemia, several ADCs have been developed for the ...
openaire   +4 more sources

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs

Data in Brief, 2018
Experimental procedures and 1H and 13C NMR of the heterotrifunctional linker used for preparation of dual drug conjugates and PBD payload are included.
Amit Kumar, Krista Kinneer, Luke Masterson, Ebele Ezeadi, Philip Howard, Herren Wu, Changshou Gao, Nazzareno Dimasi   +7 more
doaj   +1 more source

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64

Pharmaceuticals, 2023
Understanding the physicochemical properties of antibody–drug conjugates is critical to assess their quality at manufacturing and monitor them during subsequent storage.
Yukie Yoshii, Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Kimiteru Ito, Tatsuya Higashi, Hiroaki Kurihara, Makoto Ueno   +12 more
doaj   +1 more source

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]

, 2016
BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier, Hurvitz, Sara A, Krop, Ian E, Miller, Kathy, Molnar, Istvan, Reynolds, Joseph G, Riahi, Kaveh, Tripathy, Debu, Verma, Sunil, Wickham, Thomas J, Yardley, Denise A   +10 more
core   +2 more sources

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Drugs in R&D, 2018
Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global ...
Bilal H. Lashari, Yazhini Vallatharasu, Lakshmi Kolandra, Mohsin Hamid, Dipesh Uprety   +4 more
doaj   +1 more source

The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.

Chemical and pharmaceutical bulletin, 2019
A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents.
T. Nakada, K. Sugihara, Takahiro Jikoh, Yuki Abe, T. Agatsuma   +4 more
semanticscholar   +1 more source